191 related articles for article (PubMed ID: 28652880)
1. Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.
Shayegan B; Pouliot F; So A; Fernandes J; Macri J
Can Urol Assoc J; 2017 Jun; 11(6):204-209. PubMed ID: 28652880
[TBL] [Abstract][Full Text] [Related]
2. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.
Payne H; McMenemin R; Bahl A; Greene D; Staffurth J
Int J Clin Pract; 2019 Sep; 73(9):1-6. PubMed ID: 30414348
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
4. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
[TBL] [Abstract][Full Text] [Related]
5. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.
Klotz L; Shayegan B; Guillemette C; Collins LL; Gotto G; Guérette D; Jammal MP; Pickles T; Richard PO; Saad F
Can Urol Assoc J; 2018 Feb; 12(2):30-37. PubMed ID: 29680011
[TBL] [Abstract][Full Text] [Related]
6. Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.
Klotz L; Breau RH; Collins LL; Gleave ME; Pickles T; Pouliot F; Saad F
Can Urol Assoc J; 2017; 11(1-2):16-23. PubMed ID: 28443139
[TBL] [Abstract][Full Text] [Related]
7. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.
Klotz L; O'Callaghan C; Ding K; Toren P; Dearnaley D; Higano CS; Horwitz E; Malone S; Goldenberg L; Gospodarowicz M; Crook JM
J Clin Oncol; 2015 Apr; 33(10):1151-6. PubMed ID: 25732157
[TBL] [Abstract][Full Text] [Related]
8. The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial.
Dosani M; Morris WJ; Tyldesley S; Pickles T
Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):696-701. PubMed ID: 28712786
[TBL] [Abstract][Full Text] [Related]
9. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
Shore ND; Antonarakis ES; Cookson MS; Crawford ED; Morgans AK; Albala DM; Hafron J; Harris RG; Saltzstein D; Brown GA; Henderson J; Lowentritt B; Spier JM; Concepcion R
Prostate; 2020 May; 80(6):527-544. PubMed ID: 32130741
[TBL] [Abstract][Full Text] [Related]
11. Androgen metabolic pathway involved in current and emerging treatment for men with castration resistant prostate cancer: intraprostatic androgens as therapeutic targets and endocrinological biomarkers.
Hara N; Nishiyama T
Curr Drug Targets; 2014; 15(13):1215-24. PubMed ID: 25341420
[TBL] [Abstract][Full Text] [Related]
12. What do Canadian uro-oncologists believe patients should know about androgen deprivation therapy?
Tran S; Walker LM; Wassersug RJ; Matthew AG; McLeod DL; Robinson JW
J Oncol Pharm Pract; 2014 Jun; 20(3):199-209. PubMed ID: 24122850
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654
[TBL] [Abstract][Full Text] [Related]
14. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Nishiyama T
Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
[TBL] [Abstract][Full Text] [Related]
15. Post-prostatectomy adjuvant androgen deprivation therapy- Current opinions and practices of Canadian urologists.
Levitt M; Nayak AL; Fergusson DA; Lavallee LT; Morash C; Cagiannos I; Flaman AS; Breau RH
Urol Oncol; 2022 Feb; 40(2):57.e9-57.e14. PubMed ID: 34303596
[TBL] [Abstract][Full Text] [Related]
16. Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
Saad F; Fleshner N; Pickles T; Niazi T; Lukka H; Pouliot F; Martins I; Klotz L
J Urol; 2020 Sep; 204(3):416-426. PubMed ID: 32096678
[TBL] [Abstract][Full Text] [Related]
17. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
18. Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice.
Sayyid RK; Sayyid AK; Klaassen Z; Fadaak K; Goldberg H; Chandrasekar T; Ahmad A; Leao R; Perlis N; Chadwick K; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta AR; Fleshner NE
J Urol; 2018 Jan; 199(1):251-256. PubMed ID: 28751266
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
20. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
